Should MS be treated by escalation or induction therapy?
MS is a chronic, increasingly disabling disease whose long-term outcomes determine the key social, medical and economic impact of this disease. Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are prescribed to delay disease progression and to protect a patient's functional capability. The concepts of escalation and induction immunotherapy in MS represent different therapeutic strategies for the treatment of MS. Both strategies may be valuable options for patients starting on DMT, however, induction therapy mainly focuses on patients with very aggressive course of MS from the onset. Using a patient unique approach to selection of treatment, MS can be effectively control disease and may delay or even prevent the development of secondary progressive MS.
Ines
I
Lazibat
Branimir
B
Nevajda
Gordan
G
Grahovac
Vesna V
VV
Brinar
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D060828:Induction Chemotherapy / Q000379:methods*; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents